Citius Oncology, Inc. Common Stock (CTOR) is a publicly traded Healthcare sector company. As of May 21, 2026, CTOR trades at $0.82 with a market cap of $77.07M and a P/E ratio of -2.37. CTOR moved -4.61% today. Year to date, CTOR is -28.17%; over the trailing twelve months it is -7.19%. Its 52-week range spans $0.49 to $6.19. Analyst consensus is buy with an average price target of $6.00. Rallies surfaces CTOR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Hedge funds tracked by Rallies that own CTOR include Citadel Advisors and Renaissance Technologies. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Citius Oncology, Inc. Common Stock.
| Metric | Value |
|---|---|
| Price | $0.82 |
| Market Cap | $77.07M |
| P/E Ratio | -2.37 |
| EPS | $-0.34 |
| Dividend Yield | 0.00% |
| 52-Week High | $6.19 |
| 52-Week Low | $0.49 |
| Volume | 1.64K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-24.76M |
| Gross Margin | 0.00% |
1 analysts cover CTOR: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $6.00.